Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

Weisberg E, Meng C, Case A, Sattler M, Tiv HL, Gokhale PC, Buhrlage S, Wang J, Gray N, Stone R, Liu S, Bhagwat SV, Tiu RV, Adamia S, Griffin JD.

Leukemia. 2019 Aug 27. doi: 10.1038/s41375-019-0552-3. [Epub ahead of print] No abstract available.

PMID:
31455850
2.

Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma.

Bendell J, Andre V, Ho A, Kudchadkar R, Migden M, Infante J, Tiu RV, Pitou C, Tucker T, Brail L, Von Hoff D.

Clin Cancer Res. 2018 May 1;24(9):2082-2091. doi: 10.1158/1078-0432.CCR-17-0723. Epub 2018 Feb 26.

3.

Loss of epigenetic regulator TET2 and oncogenic KIT regulate myeloid cell transformation via PI3K pathway.

Palam LR, Mali RS, Ramdas B, Srivatsan SN, Visconte V, Tiu RV, Vanhaesebroeck B, Roers A, Gerbaulet A, Xu M, Janga SC, Takemoto CM, Paczesny S, Kapur R.

JCI Insight. 2018 Feb 22;3(4). pii: 94679. doi: 10.1172/jci.insight.94679. eCollection 2018 Feb 22.

4.

RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.

Chen SH, Gong X, Zhang Y, Van Horn RD, Yin T, Huber L, Burke TF, Manro J, Iversen PW, Wu W, Bhagwat SV, Beckmann RP, Tiu RV, Buchanan SG, Peng SB.

Oncogene. 2018 Feb 8;37(6):821-832. doi: 10.1038/onc.2017.384. Epub 2017 Oct 23.

PMID:
29059158
5.

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.

Yao YM, Donoho GP, Iversen PW, Zhang Y, Van Horn RD, Forest A, Novosiadly RD, Webster YW, Ebert P, Bray S, Ting JC, Aggarwal A, Henry JR, Tiu RV, Plowman GD, Peng SB.

Clin Cancer Res. 2017 Sep 15;23(18):5547-5560. doi: 10.1158/1078-0432.CCR-16-3250. Epub 2017 Jun 13.

6.

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.

Harrison CN, Schaap N, Vannucchi AM, Kiladjian JJ, Tiu RV, Zachee P, Jourdan E, Winton E, Silver RT, Schouten HC, Passamonti F, Zweegman S, Talpaz M, Lager J, Shun Z, Mesa RA.

Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.

PMID:
28602585
7.

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia.

Vadhan-Raj S, Abonour R, Goldman JW, Smith DA, Slapak CA, Ilaria RL Jr, Tiu RV, Wang X, Callies S, Cox J, Tuttle JL, Lau YK, Roeland EJ.

J Hematol Oncol. 2017 Mar 21;10(1):73. doi: 10.1186/s13045-017-0427-x.

8.

Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.

Hamilton BK, Visconte V, Jia X, Tabarroki A, Makishima H, Hasrouni E, Abounader D, Kalaycio M, Sekeres MA, Sobecks R, Duong Liu H, Bolwell B, Maciejewski JP, Copelan E, Tiu RV.

Am J Hematol. 2016 Jun;91(4):406-9. doi: 10.1002/ajh.24306. Epub 2016 Mar 14.

9.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF.

Haematologica. 2015 Sep;100(9):1117-30. doi: 10.3324/haematol.2014.114660.

10.

Non-t(6;9) and Non-Inv(3) Balanced Chromosomal Rearrangements Are Associated With Poor Survival Outcomes in Myelodysplastic Syndromes.

Ai J, Visconte V, Tabarroki A, Hasrouni E, Hamilton BK, Mukherjee S, Kalaycio M, Sobecks R, Advani AS, Sekeres MA, Shetty S, Tiu RV.

Clin Lymphoma Myeloma Leuk. 2015 Aug;15(8):489-95. doi: 10.1016/j.clml.2015.03.017. Epub 2015 Apr 2.

PMID:
25977195
11.

Safe and effective use of ponatinib in a patient with chronic myeloid leukemia and acute venous thromboembolism on therapeutic anti-coagulation.

Shomali W, Redmond C, Bogati S, Zimmerman C, Visconte V, Tabarroki A, Kalaycio M, Tiu RV.

Leuk Lymphoma. 2016;57(1):193-5. doi: 10.3109/10428194.2015.1036259. Epub 2015 Jun 18. No abstract available.

PMID:
25942382
12.

Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis.

Visconte V, Tabarroki A, Hasrouni E, Maciejewski JP, Hsi ED, Tiu RV, Rogers HJ.

Leuk Lymphoma. 2016;57(1):212-5. doi: 10.3109/10428194.2015.1045895. Epub 2015 Jun 25. No abstract available.

PMID:
25926061
13.

Current and novel therapeutic approaches in myelodysplastic syndromes.

Estephan F, Tiu RV.

J Community Support Oncol. 2014 Jul;12(7):236-49. doi: 10.12788/jcso.0057. Review.

PMID:
25830232
14.

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Savona MR, Malcovati L, Komrokji R, Tiu RV, Mughal TI, Orazi A, Kiladjian JJ, Padron E, Solary E, Tibes R, Itzykson R, Cazzola M, Mesa R, Maciejewski J, Fenaux P, Garcia-Manero G, Gerds A, Sanz G, Niemeyer CM, Cervantes F, Germing U, Cross NC, List AF; MDS/MPN International Working Group.

Blood. 2015 Mar 19;125(12):1857-65. doi: 10.1182/blood-2014-10-607341. Epub 2015 Jan 26.

15.

Impact of vancomycin-resistant enterococcal bacteremia on outcome during acute myeloid leukemia induction therapy.

Ornstein MC, Mukherjee S, Keng M, Elson P, Tiu RV, Saunthararajah Y, Maggiotto A, Schaub M, Banks D, Advani A, Kalaycio M, Maciejewski JP, Sekeres MA.

Leuk Lymphoma. 2015;56(9):2536-42. doi: 10.3109/10428194.2014.1003557. Epub 2015 Feb 20.

PMID:
25563427
16.

Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.

Visconte V, Tiu RV, Rogers HJ.

Blood Res. 2014 Dec;49(4):216-27. doi: 10.5045/br.2014.49.4.216. Epub 2014 Dec 23. Review.

17.

Cyclosporine dependent pure red cell aplasia: a case presentation.

Al-Issa K, Visconte V, Rogers HJ, Dembla V, Lichtin AE, Tiu RV.

Blood Cells Mol Dis. 2015 Mar;54(3):281-3. doi: 10.1016/j.bcmd.2014.11.013. Epub 2014 Nov 25. No abstract available.

PMID:
25488615
18.

Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.

Visconte V, Tabarroki A, Zhang L, Parker Y, Hasrouni E, Mahfouz R, Isono K, Koseki H, Sekeres MA, Saunthararajah Y, Barnard J, Lindner D, Rogers HJ, Tiu RV.

J Hematol Oncol. 2014 Dec 7;7:89. doi: 10.1186/s13045-014-0089-x.

19.

Regulation of Stat5 by FAK and PAK1 in Oncogenic FLT3- and KIT-Driven Leukemogenesis.

Chatterjee A, Ghosh J, Ramdas B, Mali RS, Martin H, Kobayashi M, Vemula S, Canela VH, Waskow ER, Visconte V, Tiu RV, Smith CC, Shah N, Bunting KD, Boswell HS, Liu Y, Chan RJ, Kapur R.

Cell Rep. 2014 Nov 20;9(4):1333-48. doi: 10.1016/j.celrep.2014.10.039. Epub 2014 Nov 13.

20.
21.

Screening for SF3B1 mutations is a useful tool to differentiate between acquired clonal and non-clonal sideroblastic anemia.

Visconte V, Tabarroki A, Gerace CJ, Al-Issa K, Hsi ED, Rogers HJ, Sekeres MA, Silver BJ, Lichtin AE, Mukherjee S, Tiu RV.

Leuk Lymphoma. 2015 Jun;56(6):1888-90. doi: 10.3109/10428194.2014.976821. Epub 2014 Nov 14. No abstract available.

PMID:
25330446
22.

ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.

Shivarov V, Gueorguieva R, Ivanova M, Tiu RV.

Leuk Lymphoma. 2015 Jun;56(6):1881-3. doi: 10.3109/10428194.2014.974596. Epub 2015 Jan 8. No abstract available.

PMID:
25308295
23.

Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.

Stein BL, Moliterno AR, Tiu RV.

Ann Hematol. 2014 Dec;93(12):1965-76. doi: 10.1007/s00277-014-2205-y. Epub 2014 Oct 2. Review.

PMID:
25270596
24.

Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.

de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, Visconte V, Tabarroki A, Duarte AS, Barra FF, Vassalo J, Rogers HJ, Lorand-Metze I, Tiu RV, Costa FF, Olalla Saad ST, Traina F.

Leuk Res. 2014 Oct;38(10):1245-51. doi: 10.1016/j.leukres.2014.07.010. Epub 2014 Aug 1.

25.

Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.

Estephan F, Rogers HJ, Visconte V, Tabarroki A, Ai J, Duong HK, Kalaycio M, Tiu RV.

Leuk Lymphoma. 2015 Mar;56(3):811-3. doi: 10.3109/10428194.2014.935367. Epub 2014 Jul 17. No abstract available.

PMID:
24956141
26.

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron.

Visconte V, Avishai N, Mahfouz R, Tabarroki A, Cowen J, Sharghi-Moshtaghin R, Hitomi M, Rogers HJ, Hasrouni E, Phillips J, Sekeres MA, Heuer AH, Saunthararajah Y, Barnard J, Tiu RV.

Leukemia. 2015 Jan;29(1):188-95. doi: 10.1038/leu.2014.170. Epub 2014 May 23.

PMID:
24854990
27.

Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10).

Visconte V, Tabarroki A, Zhang L, Hasrouni E, Gerace C, Frum R, Ai J, Advani AS, Duong HK, Kalaycio M, Saunthararajah Y, Sekeres MA, His ED, Shetty S, Rogers HJ, Tiu RV.

Am J Hematol. 2014 Aug;89(8):862. doi: 10.1002/ajh.23755. Epub 2014 May 16. No abstract available.

28.

Molecular genetics of myelofibrosis and its associated disease phenotypes.

Tabarroki A, Tiu RV.

Transl Med UniSa. 2014 Feb 4;8:53-64. eCollection 2014 Jan.

29.

Molecular pathogenesis of myelodysplastic syndromes.

Visconte V, Selleri C, Maciejewski JP, Tiu RV.

Transl Med UniSa. 2014 Feb 4;8:19-30. eCollection 2014 Jan.

30.

Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts.

Tabarroki A, Saunthararajah Y, Visconte V, Cinalli T, Colaluca K, Rogers HJ, Sekeres MA, Duong HK, Stein BL, Tiu RV.

Leuk Lymphoma. 2015 Feb;56(2):497-9. doi: 10.3109/10428194.2014.916805. Epub 2014 May 27. No abstract available.

PMID:
24766471
31.

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A.

Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800. Epub 2014 Mar 13.

32.

Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.

Mukherjee S, Reddy CA, Ciezki JP, Abdel-Wahab M, Tiu RV, Copelan E, Advani AA, Saunthararajah Y, Paulic K, Hobson S, Maciejewski JP, Bolwell BJ, Kalaycio M, Dreicer R, Klein EA, Sekeres MA.

J Natl Cancer Inst. 2014 Mar;106(3):djt462. doi: 10.1093/jnci/djt462. Epub 2014 Feb 27.

PMID:
24577815
33.

Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca(2+): some mechanistic and therapeutic implications.

Shivarov V, Ivanova M, Tiu RV.

Blood Cancer J. 2014 Feb 21;4:e185. doi: 10.1038/bcj.2014.7. No abstract available.

34.

Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.

Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED.

Haematologica. 2014 May;99(5):821-9. doi: 10.3324/haematol.2013.096420. Epub 2014 Jan 24.

35.

Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.

Tabarroki A, Lindner DJ, Visconte V, Zhang L, Rogers HJ, Parker Y, Duong HK, Lichtin A, Kalaycio ME, Sekeres MA, Mountantonakis SE, Heresi GA, Tiu RV.

Leukemia. 2014 Jul;28(7):1486-93. doi: 10.1038/leu.2014.5. Epub 2014 Jan 10.

PMID:
24406841
36.

Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.

Tiu RV, Sekeres MA.

Curr Opin Hematol. 2014 Mar;21(2):131-40. doi: 10.1097/MOH.0000000000000021. Review.

PMID:
24378705
37.

Sex differences in the incidence of chronic myeloid leukemia.

Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, Gale RP, Sachs RK.

Radiat Environ Biophys. 2014 Mar;53(1):55-63. doi: 10.1007/s00411-013-0507-4. Epub 2013 Dec 13.

38.

Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.

Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, Terebelo HR, Ortega GL, Lyons RM, Tiu RV, Winton EF, Natrajan K, Odenike O, Claxton D, Peng W, O'Neill P, Erickson-Viitanen S, Leopold L, Sandor V, Levy RS, Kantarjian HM, Verstovsek S.

J Hematol Oncol. 2013 Oct 29;6(1):81. doi: 10.1186/1756-8722-6-81.

39.

Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.

Ornstein MC, Mukherjee S, Mohan S, Elson P, Tiu RV, Saunthararajah Y, Kendeigh C, Advani A, Kalaycio M, Maciejewski JP, Sekeres MA.

Am J Hematol. 2014 Feb;89(2):168-73. doi: 10.1002/ajh.23605. Epub 2013 Nov 21.

40.

Pak and Rac GTPases promote oncogenic KIT-induced neoplasms.

Martin H, Mali RS, Ma P, Chatterjee A, Ramdas B, Sims E, Munugalavadla V, Ghosh J, Mattingly RR, Visconte V, Tiu RV, Vlaar CP, Dharmawardhane S, Kapur R.

J Clin Invest. 2013 Oct;123(10):4449-63. doi: 10.1172/JCI67509. Epub 2013 Sep 16.

41.

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Traina F, Visconte V, Elson P, Tabarroki A, Jankowska AM, Hasrouni E, Sugimoto Y, Szpurka H, Makishima H, O'Keefe CL, Sekeres MA, Advani AS, Kalaycio M, Copelan EA, Saunthararajah Y, Olalla Saad ST, Maciejewski JP, Tiu RV.

Leukemia. 2014 Jan;28(1):78-87. doi: 10.1038/leu.2013.269. Epub 2013 Sep 18.

PMID:
24045501
42.

Epidemiology and risk factors for infections in myelodysplastic syndromes.

Sullivan LR, Sekeres MA, Shrestha NK, Maciejewski JP, Tiu RV, Butler R, Mossad SB.

Transpl Infect Dis. 2013 Dec;15(6):652-7. doi: 10.1111/tid.12130. Epub 2013 Sep 9.

PMID:
24010918
43.

SF3B1 mutations are infrequently found in non-myelodysplastic bone marrow failure syndromes and mast cell diseases but, if present, are associated with the ring sideroblast phenotype.

Visconte V, Tabarroki A, Rogers HJ, Hasrouni E, Traina F, Makishima H, Hamilton BK, Liu Y, O'Keefe C, Lichtin A, Horwitz L, Sekeres MA, Hsieh FH, Tiu RV.

Haematologica. 2013 Sep;98(9):e105-7. doi: 10.3324/haematol.2013.090506. Epub 2013 Jul 5. No abstract available.

44.

Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.

Wenzell CM, Gallagher EM, Earl M, Yeh JY, Kusick KN, Advani AS, Kalaycio ME, Mukherjee S, Tiu RV, Maciejewski JP, Sekeres MA.

Am J Hematol. 2013 Oct;88(10):906-9. doi: 10.1002/ajh.23530. Epub 2013 Aug 30.

45.

Myelodysplastic syndromes: recent advancements in risk stratification and unmet therapeutic challenges.

Bejar R, Tiu RV, Sekeres MA, Komrokji RS.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e256. Review.

46.

Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.

Liu Y, Tabarroki A, Billings S, Visconte V, Rogers HJ, Hasrouni E, Englehaupt R, Kalaycio M, Sekeres MA, Saunthararajah Y, Tiu RV.

Leuk Lymphoma. 2014 Feb;55(2):447-9. doi: 10.3109/10428194.2013.802315. Epub 2013 Jun 24. No abstract available.

PMID:
23647061
47.

Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.

Sonbol MB, Firwana B, Zarzour A, Morad M, Rana V, Tiu RV.

Ther Adv Hematol. 2013 Feb;4(1):15-35. doi: 10.1177/2040620712461047.

48.

Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease.

Tabarroki A, Visconte V, Rogers HJ, Sekeres MA, Samaras C, Lichtin A, Duong HK, Englehaupt R, Cinalli T, Dodd K, Desamito J, Rouphail B, Altman JK, Stein BL, Tiu RV.

Leuk Lymphoma. 2014 Jan;55(1):213-6. doi: 10.3109/10428194.2013.797086. Epub 2013 Jun 12. No abstract available.

PMID:
23607256
49.

Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.

Stein BL, Tiu RV.

J Interferon Cytokine Res. 2013 Apr;33(4):145-53. doi: 10.1089/jir.2012.0120. Review.

PMID:
23570380
50.

Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.

Adès L, Sekeres MA, Wolfromm A, Teichman ML, Tiu RV, Itzykson R, Maciejewski JP, Dreyfus F, List AF, Fenaux P, Komrokji RS.

Leuk Res. 2013 Jun;37(6):609-13. doi: 10.1016/j.leukres.2013.01.004. Epub 2013 Feb 12.

PMID:
23415110

Supplemental Content

Support Center